Loss of a single allele of SHIP exacerbates the immunopathology of Pten heterozygous mice

Genes and Immunity

Volumn 4, Issue 1, 2003, Pages 60-66

  Moody, J L ^a,b   Pereira, C G ^a   Magil, A ^a   Fritzler, M J ^b   Jirik, F R ^a,b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c NONE   (Canada)

Author keywords

Autoantibodies; Lipid mediators; Lupus; Phosphatidylinositol phosphatases

Indexed keywords

3' INOSITOL PHOSPHATASE; 5' INOSITOL PHOSPHATASE; AUTOANTIBODY; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; UNCLASSIFIED DRUG; INPPL1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR SUPPRESSOR PROTEIN;

ALLELE; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; GENE DOSAGE; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY; HYPERGAMMAGLOBULINEMIA; IMMUNOPATHOLOGY; IMMUNOREGULATION; KIDNEY DISEASE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; GENETICS; HETEROZYGOSITY LOSS; HETEROZYGOTE DETECTION; IMMUNOLOGY; KIDNEY; LYMPHATIC SYSTEM DISEASE; MOUSE MUTANT; PATHOLOGY; SPLEEN;

ANIMALS; CELLS, CULTURED; FEMALE; HETEROZYGOTE DETECTION; KIDNEY; LOSS OF HETEROZYGOSITY; LYMPHATIC DISEASES; MICE; MICE, MUTANT STRAINS; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; SPLEEN; TUMOR SUPPRESSOR PROTEINS;

EID: 0037699006     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6363903     Document Type: Article

References (36)

1. Kotzin BL. Systemic lupus erythematosus. Cell 1996; 85: 303-306.
2. Roberton CA, Vyse TJ. The genetics of Systemic Lupus erythematosus. Exp Nephrol 2000; 8: 194-202.
3. Vyse TJ, Todd JA. Genetic analysis of autoimmune disease. Cell 1996; 85: 311-318.
4. Foster MH. Relevance of systemic lupus erythematosus nephritis animal models to human disease. Semin Nephrol 1999; 19: 12-24.
5. Inaoki M, Sato S, Weintraub BC, Goodnow CC, Tedder TF. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J Exp Med 1997; 186: 1923-1931.
6. Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc (gamma) RIIB-deficient mice results from strain-specific epistasis. Immunity 2000; 13: 277-285.
7. Goodnow CC. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci USA 1996; 93: 2264-2271.
8. Cornall RJ, Cyster JG, Hibbs ML et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 1998; 8: 497-508.
9. Satterthwaite AB, Willis F, Kanchanastit P et al. A sensitized genetic system for the analysis of murine B lymphocyte signal transduction pathways dependent on Bruton's tyrosine kinase. Proc Natl Acad Sci USA 2000; 97: 6687-6692.
10. Campbell KS. Signal transduction from the B cell antigen-receptor. Curr Opin Immunol 1999; 11: 256-264.
11. Ward SG, June CH, Olive D. PI 3-kinase: a pivotal pathway in T-cell activation? Immunol Today 1996; 17: 187-197.
12. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphomositide-dependent phosphorylation. Annu Rev Biochem 1999; 68: 965-1014.
13. Martin TF. Phosphoinositide lipids as signaling molecules: common themes for signal transduction, cytoskeletal regulation, and membrane trafficking. Annu Rev Cell Dev Biol 1998; 14: 231-264.
14. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273: 13375-13378.
15. Huber M, Helgason CD, Damen JE et al. The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation. Proc Natl Acad Sci USA 1998; 95: 11330-11335.
16. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19: 348-355.
17. Suzuki A, de la Pompa JL, Stambolic V et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998; 8: 1169-1178.
18. Podsypanina K, Ellenson LH, Nemes A et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999; 96: 1563-1568.
19. +/- mice. Science 1999; 285: 2122-2125.
20. Suzuki A, Yamaguchi MT, Ohteki T et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001; 14: 523-534.
21. Borlado LR, Redondo C, Alvarez B et al. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. Faseb J 2000; 14: 895-903.
22. Mohan C, Morel L, Yang P, Wakeland EK. Genetic dissection of systemic lupus erythematosus pathogenesis: Sle2 on murine chromosome 4 leads to B cell hyperactivity. J Immunol 1997; 159: 454-465.
23. Fulpius T, Spertini F, Reininger L, Izui S. Immunoglobulin heavy chain constant region determines the pathogenicity and the antigen-binding activity of rheumatoid factor. Proc Natl Acad Sci USA 1993; 90: 2345-2349.
24. Martin L, Pauls JD, Ryan JP, Fritzler MJ. Identificationof a subset of patients with scleroderma with severe pulmonary and- vascular disease by the presence of autoantibodies to centromere and histone. Ann Rheum Dis 1993; 52: 780-784.
25. Berden JH. Lupus nephritis. Kidney Int 1997; 52: 538-558.
26. von Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic disease. Semin Arthritis Rheum 1995; 24: 323-358.
27. Burlingame RW, Boey ML, Starkebaum G, Rubin RL. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994; 94: 184-192.
28. Burlingame RW, Rubin RL, Balderas RS, Theofilopoulos AN. Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen. J Clin Invest 1993; 91: 1687-1696.
29. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985; 37: 269-390.
30. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381-395.
31. Helgason CD, Damen JE, Rosten P et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev 1998; 12: 1610-1620.
32. Brauweiler A, Tamir I, Dal Porto J et al. Differential regulation of B cell development, activation, and death by the src homology 2 domain-containing 5′ inositol phosphatase (SHIP). J Exp Med 2000; 191: 1545-1554.
33. -/- mice. J Exp Med 2000; 191: 781-794.
34. Walker SM, Downes CP, Leslie NR. TPIP: a novel phosphoinositide 3-phosphatase. Biochem J 2001; 360(Pt 2): 277-283.
35. Raizis AM, Ferguson MM, Robinson BA, Atkinson CH, George PM. Identification of a novel PTEN mutation (L139X) in a patient with Cowden disease and Sjogren's syndrome. Mol Pathol 1998; 51: 339-341.
36. Lindqvist AK, Steinsson K, Johanneson B et al. A susceptibility locus for human systemic lupus erythematosus (hSLE1) on chromosome 2q. J Autoimmun 2000; 14: 169-178.